CirTran 3Q 2026: Revenue $663.51K, EPS ($0.06) — 10-Q Summary

CirTran reported 3Q 2026 revenue of $663.51K, up 47.9% YoY, and narrowed net loss to $285,162. Higher vapor product demand boosted sales, while reduced SG&A expenses helped lower operating loss. Gross profit increased to $230,196 from $177,826.

Original reporting
Published Nov 13, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CirTran 3Q 2026: Revenue $663.51K, EPS ($0.06) — 10-Q Summary — source image
Decision brief

The 30-second read

$CIRXNeutralLow
01

Why it matters

The earnings beat on loss reduction may prompt short‑term buying, but the micro‑cap nature limits broader market impact.

02

Market read

Primary earnings disclosure for a micro‑cap; modest trading relevance.

03

What to watch

Potential regulatory scrutiny on vapor products could offset short‑term earnings optimism.

Relevance 6/10Novelty 7/10Timing: after‑hours

Background

CirTran Corp (CIRX) released its Q3 2026 10‑Q, highlighting a 47.9% YoY revenue increase and a reduction in net loss.

Company-level read

Ticker impact

$CIRXNeutralMedium confidence
Context

CirTran Corp filed its 10‑Q showing Q3 revenue of $663.5K and a narrowed loss, the first public disclosure of these numbers.

Expected impact

potential slight upside as the market prices in the improved loss profile

Evidence & confidence

Micro‑cap earnings with better‑than‑expected loss reduction can attract short‑term buying, but limited liquidity caps move size.

Market effects

Improved performance may signal modest tailwinds for the vapor‑product niche, but impact on broader sector is limited.

No significant regional effect; company is US‑based micro‑cap.

Low global relevance due to small size and niche market.

Counterpoint

Despite narrowed loss, revenue remains modest; the stock may still be overvalued relative to peers.

Key entities

  • CirTran Corp

    Micro‑cap vapor‑product manufacturer reporting Q3 2026 results.

Related articles

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$YTRAMed

Yatra Online Inc (YTRA) (Q2 2027) Earnings Call Highlights: Air and Corporate Travel

Yatra Online (YTRA) reported Q2 2027 revenue from operations down 39% YoY to INR2,136M (~$22M) due to lower MICE volumes. Gross margin stayed flat at INR1,255M (~$13M). Adjusted EBITDA swung to negative INR32M (~negative $0.3M). CEO Gupta noted MICE recovery signs, TravelPro and Recap initiatives progress, and AI efficiency gains. Standalone hotels grew 20% YoY. H1 FY27 revenue declined 28% YoY to INR4,015M (~$42M).

$PARKHighAI 8/10

Park Dental Partners Inc (PARK) (Q3 2026) Earnings Call Highlights: Revenue Climbs 6%

Park Dental Partners Inc (PARK) reported Q3 2026 revenue of $64.9M, up 6% YoY, driven by acquisitions and clinical hours. The company acquired Village Family Dental for $39.1M, funded with cash, a small credit line draw, and stock. PARK updated its 2026 revenue outlook to $262M-$265M and adjusted EBITDA to $21.2M-$22.2M. Gross margin declined due to higher salaries and cybersecurity costs. The acquisition adds 47 doctors and expands PARK's footprint to North Carolina.